Original articleLessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19
Keywords
SARS-CoV-2
COVID-19
Anakinra
Tocilizumab
IL-1
IL-6
Abbreviations
COVID-19
coronavirus disease 2019
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2-related
IL
interleukin
TNF-α
tumor necrosis factor-α, sHLH, haemophagocytic lymphohistiocytosis
MAS
macrophage activation syndrome
IVIG
intravenous infusions of γ-globulins
JAK
Janus kinase
BMI
body mass index
CRP
C-reactive protein
LDH
lactate dehydrogenase
OR
odds ratio
HR
hazard ratio
RCTs
randomized controlled trials
Cited by (0)
Note: This study has been presented as an abstract in the 19th European Congress of Internal Medicine, European Federation of Internal Medicine, March 18-20, 2021.
© 2021 Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.